Geron Corporation stock reports 17 percent revenue growth

Published on 10/06/2026 at 13:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Geron Corporation stock was last at USD 1.21 on October 5, with a USD 1.04 to USD 2.01 52-week range. Five analysts give a Buy consensus and USD 4.25 target.

GERN, US3741631036, Illustration mit AI erstellt.

Geron Corporation (ISIN US3741631036) delivered USD 57.5 million in Q2 2026 net revenue, up 17 percent year over year, according to Quartr. GERN was last at USD 1.21 on Nasdaq on October 5, 2026, at 4:00 p.m. ET, up 0.83 percent from the prior close.

Revenue reaches a new checkpoint

The Q2 figure marked Geron's highest quarterly RYTELO revenue since the drug launched, while the company recorded three consecutive quarters of revenue growth, Quartr reported on September 9, 2026. The commercial result gives the stock a measurable operating anchor after a period in which investors have focused heavily on the company's clinical pipeline.

Geron is targeting 2026 RYTELO net revenue of USD 220 million to USD 240 million. At the Cantor Fitzgerald healthcare conference, management indicated that results were tracking toward the midpoint to high end of that range, with operating expenses also guided at USD 230 million to USD 240 million, according to Quartr.

Analysts see a wider valuation gap

Stockanalysis lists a Buy consensus from 5 analysts and an average price target of USD 4.25. The target sits well above the October 5 trading level, making future revenue conversion and progress toward profitability central to the valuation discussion.

The same operating picture carries a clear counterweight: Q2 net income was a loss of USD 16.68 million, while operating cash flow was negative USD 15.83 million for the quarter ended June 30, 2026. Geron therefore combines accelerating commercial revenue with continued cash consumption, a tension that keeps execution in RYTELO and the myelofibrosis pipeline important for shareholders.

GERN remains near its yearly floor

At USD 1.21, Geron stock stood USD 0.17 above its 52-week low of USD 1.04 and USD 0.80 below its 52-week high of USD 2.01 on October 5, 2026. The market capitalization was USD 776.2 million and volume reached 6,365,994 shares, keeping the commercial milestones ahead of the next results update as the key valuation test.